AbbVie has bought an exclusive option to acquire Mitokinin once the UCSF spinout completes IND-enabling studies for its Parkinson’s treatment.

Mitokinin, a US-based developer of treatments for neurodegenerative diseases based on research at University of California, San Francisco, sold an exclusive buyout option to pharmaceutical firm AbbVie on Tuesday. AbbVie has made an upfront payment, though financial terms were not disclosed. It will have the right to acquire Mitokinin once the spinout has completed investigational…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.